Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Efficacy and Safety of 500mg of Fulvestrant as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Brigham and Women's Hospital
Massachusetts General Hospital
Lowell General Hospital
University of Colorado, Denver
University of Maryland Greenebaum Cancer Center
South Shore Hospital
Information provided by (Responsible Party):
Steven Come, MD, Beth Israel Deaconess Medical Center
ClinicalTrials.gov Identifier:
NCT00585507
First received: December 22, 2007
Last updated: January 15, 2014
Last verified: January 2014

December 22, 2007
January 15, 2014
April 2004
June 2014   (final data collection date for primary outcome measure)
To assess the clinical benefit rate for subjects receiving this dose and schedule of fulvestrant. [ Time Frame: TBD ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00585507 on ClinicalTrials.gov Archive Site
  • Overall objective response rate, time to response, duration of response, duration of clinical benefit, and time to progression. [ Time Frame: TBD ] [ Designated as safety issue: No ]
  • Assessment of adverse events [ Time Frame: 4 years ] [ Designated as safety issue: Yes ]
  • Assessment of pharmacokinetics of this dose and schedule of fulvestrant. [ Time Frame: 4 years ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Efficacy and Safety of 500mg of Fulvestrant as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
A Phase II Multi-Center Study to Evaluate the Efficacy and Safety of 500mg of Fulvestrant (Faslodex) as a First Line Hormonal Treatment in Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer

Fulvestrant has proven effective in the treatment of hormone receptor positive metastatic breast cancer. The dose used in studies so far has been well tolerated and may be too low for optimal effectiveness. In this study, a higher dose will be used to see whether an improved outcome will result.

  • Fulvestrant will be administered by intramuscular injection on day 1, day 15 and day 29 and then every 28 days thereafter.
  • Participants will have a physical examination and blood work performed on each treatment date. After teh study treatment has been completed, the physical examinations will be done every three months for the first 2 years, every 6 months for years 2-5, and annually after 5 years.
  • Participants may remain on study treatment until disease progression or until they experience serious side effects.
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Breast Cancer
Drug: Fulvestrant
500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.
Other Name: Faslodex
Experimental: single
fulvestrant 500mg
Intervention: Drug: Fulvestrant
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
40
July 2014
June 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Female
  • 18 years of age or older
  • Histologically confirmed adenocarcinoma of the breast progressing local-regional or metastatic disease that is not considered amenable to curative treatment
  • Evidence of hormone sensitivity of primary or secondary tumor tissue
  • Postmenopausal as defined by criteria listed in protocol
  • May have had adjuvant endocrine therapy if discontinued at least 12 months prior to inclusion. Subjects who have had minimal exposure to adjuvant or first line metastatic endocrine treatment during the 12 months prior to study enrollment can be eligible with overall PI and sponsor permission
  • Prior trastuzumab and biologic therapy is allowed, but must be discontinued more than 2 weeks prior to inclusion
  • Presence of measurable or evaluable, nonmeasurable, disease. Any x-rays and scans for assessment of measurable disease must be performed with 28 days prior to registration
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0,1 or 2

Exclusion Criteria:

  • Presence of life-threatening metastatic disease
  • Endocrine therapy the advanced disease setting
  • Systemic chemotherapy, whether as adjuvant therapy or for advanced disease, within previous 4 weeks
  • Trastuzumab or biologic therapy within previous 2 weeks
  • Extensive radiation therapy within the last 2 weeks
  • Prior adjuvant or neoadjuvant treatment with fulvestrant is not allowed
  • Concomitant anticancer treatments
  • Chronic bisphosphonates for hypercalcemia or prevention of bone metastases
  • Subjects receiving long-term anticoagulant therapy with warfarin
  • Estrogen replacement therapy within 6 months of trial entry
  • Previous or current systems malignancy within the past 3 years
  • Treatment with non approved or investigational drug within 2 weeks before study entry
  • Any evidence of severe or uncontrolled systemic disease
  • History of bleeding diathesis
  • Any severe concomitant condition which makes it undesirable for the subject to participate in the study or which would jeopardize compliance with the study protocol
Female
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00585507
04-016
Yes
Steven Come, MD, Beth Israel Deaconess Medical Center
Beth Israel Deaconess Medical Center
  • Dana-Farber Cancer Institute
  • Brigham and Women's Hospital
  • Massachusetts General Hospital
  • Lowell General Hospital
  • University of Colorado, Denver
  • University of Maryland Greenebaum Cancer Center
  • South Shore Hospital
Principal Investigator: Steven Come, MD Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP